RECOMBINANT ERYTHROPOIETIN FOR MYELODYSPLASTIC SYNDROMES

Recombinant human erythropoietin in patients with myelodysplastic syndromes.

As anemia is frequently the main problem in myelodysplastic syndromes (MDS), we studied the efficacy of human erythropoietin (rhEpo) in stimulating the erythroid lineage in 14 patients, starting with 40 U/kg three times a week and doubling the dose every 6 weeks until a response was observed. The highest doses administered were 80 (n = 1), 160 (n = 4), 320 (n = 8) and 640 U/kg (n = 1). One pati...

Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.

Twenty patients with myelodysplastic syndromes (MDS) entered a randomized, placebo-controlled, double-blind trial designed to evaluate the efficacy and toxicity of high doses of recombinant human erythropoietin (rhEPO). Patients completing the trial were eligible to receive rhEPO as part of an open-label study. Eighteen patients were transfusion dependent; 10 had refractory anemia (RA), and 10 ...

Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.

Circadian rhythm of serum erythropoietin in myelodysplastic syndromes.

Myelodysplastic syndromes (MSD) are a group of clonal disorders of the hemopoietic stem cell, often evolving in acute leukemia. They are characterized by anemia, and it has been attributed either to a deficiency in erythropoietin (EPO) secretion or to a resistance to EPO itself. Since in healthy subjects the serum circulating EPO levels fluctuate during the day, the aim of the study was to inve...

Myelodysplastic Syndromes Myelodysplastic syndromes: recent advances

Etiology of myelodysplastic syndromes The models for the development of sporadic MDS suggest the role of cumulative environmental exposures in genetically predisposed individuals. There is increasing evidence for a complex genetic predisposition to MDS involving naturally occurring DNA polymorphisms in genes that mediate DNA repair and metabolize environmental carcinogens.3 Large epidemiologic ...